BD (China) | BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit http://www.bd.com. |
M3dicine | At M3DICINE, we design sophisticated and elegant medical devices that are powered by intuitive and intelligent software. Powerful devices that effortlessly capture vital signs at the point of care and in real-time for the new era of personalized and precision medicine. We believe in a future of healthcare where our devices empower all healthcare professionals and patients to understand and manage health better. |
Recovery Plus | The company is the very first digital therapeutics developer within China. By providing chronic disease patients with AI-based remote rehabilitation therapies and increasing their life quality, we are devoted in lifestyle interference. After many years of independent clinical R&D, our APP Recovery Plus was approved by NMPA in Nov. 2020, which was the first of this kind in China. We are also dedicated in nutritional rehabilitation. We have our own smart nutrition evaluation program and foods for special medical purposes, and we have successfully conducted clinical researches with Chinese top-tier hospitals and have acquired critical data. |
Trendlines | Trendlines invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies. We invest principally through our incubators: our two Israeli government-franchised incubators, Trendlines Medical and Trendlines Agtech, our Singapore incubators, Trendlines Medical Singapore and AFIC – an agrifood incubator, our in-house innovation center, Trendlines Labs, and our funds: the Trendlines Agrifood Fund and the Bayer Trendlines Ag Innovation Fund. As intensely hands-on investors, we are involved in all aspects of our portfolio companies from technology development to business building. Simply stated, we create and develop companies to improve the human condition. |
Escala Medical | Escala is a femtech company based in Israel. Our vision is a better quality of life to all women, everywhere. We develop life-changing repair solutions for women with Pelvic Organ Prolapse, a condition that affects nearly 50% of all women. Our innovative, patented technology addresses a huge unmet need – it replaces surgery and will help millions of women worldwide regain an improved quality of life. We successfully completed our first clinical study and are expecting FDA clearance and CE approval during 2022. Escala’s team combines proven leadership, innovation and experience in women’s healthcare. |
ElastiMed | ElastiMed has developed a wearable medical device, designed to improve circulation in the legs, treating patients suffering from venous and lymphatic diseases. The device is based on a Smart Material technology, to continuously massage the legs throughout the day, without disturbing the patient’s daily routine. Integrated sensors monitor the patient’s condition, to increase patient’s engagement and allowing for personalized treatment and remote monitoring. The device is expected to provide a comfortable and effective treatment option to treat leg swelling, prevent complications and improve the quality of life. |
Continale Medical | Continale is a company focused on improve the quality of life in patients suffering from urinary incontinence. Continale has developed a user-friendly device that provides a safe, minimally invasive solution with high patient compliance that mitigates involuntary urinary leakage associated with stress urinary incontinence (SUI). |
Omeq Medical | Omeq is a privately funded medical technology company, developing a first product for safe and accurate epidural placement with a sensor-based, single-use device. Omeq has been supported by grants from the Israeli Innovation Authority and is a portfolio company of The Trendlines Group Ltd. |
densys3D | densys3D has a new inexpensive fully patented technology and product for 3D intra oral scanning, the front end of all dental treaments. |
InfanDx | InfanDx AG is a privately held company focusing on the development and commercialization of novel diagnostic solutions for acute and critical care conditions in newborns. The Company’s proprietary lead product in clinical development is the InfanDx HypoxE® Test designed for the early a reliable identification of hypoxic-ischemic encephalopathy (HIE). |
Spear Bio | Spear Bio Inc. has developed the world’s first quantitative neutralizing antibody titer (NAb titer) for SARS-CoV-2 that can use a self-collected, dried blood spot (DBS) sample, enabling answers to questions such as “did this vaccination work in me?”, and other related public health issues. |